SCHEMBL6480755

SCHEMBL6480755

COc1ccc2[nH]c([S+]([O-])Cc3ccccc3N(C)C)nc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
ATP4A P20648 3/20 0.38
ATP4B P51164 3/20 0.38
ALDH1A1 P00352 9/20 0.35
KDM4E B2RXH2 9/20 0.35
RAB9A P51151 7/20 0.35
NPC1 O15118 7/20 0.35
SMN1; SMN2 Q16637 6/20 0.35
MEN1 O00255 6/20 0.35
KMT2A Q03164 6/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
NQO2 P16083 1/20 0.35
HSD17B10 Q99714 5/20 0.34
HPGD P15428 4/20 0.34
TP53 P04637 3/20 0.34
TSHR P16473 3/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9395894 0.91 PRMT5 (0.46) PRMT5WDR77ATP4AATP4BALDH1A1
SCHEMBL6481712 0.91 CYP1A2 (0.35) PRMT5WDR77ATP4AATP4BALDH1A1
SCHEMBL9395764 0.89 ALDH1A1 (0.38) PRMT5WDR77ATP4AATP4BALDH1A1
SCHEMBL10712467 0.88 ATP4A (0.35) PRMT5WDR77ATP4AATP4BKDM4E
SCHEMBL6481789 0.87 ATP4A (0.36) PRMT5WDR77ATP4AATP4BALDH1A1
SCHEMBL9395810 0.87 ATP4A (0.43) PRMT5WDR77ATP4AATP4BALDH1A1
SCHEMBL10712255 0.86 ALDH1A1 (0.34) PRMT5WDR77ALDH1A1KDM4ERAB9A
SCHEMBL10713745 0.86 RUNX1 (0.35) ATP4AATP4BRAB9ANPC1SMN1; SMN2
SCHEMBL9678434 0.86 PDE10A (0.39) PRMT5WDR77ATP4AATP4BALDH1A1
SCHEMBL10699890 0.85 ALDH1A1 (0.38) ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 US claimed
US-5945425-A ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE G.D. SEARLE & CO. (US) 1999-08-31 US claimed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 WO claimed
EP-0232399-A1 NEW AMINES, PROCESS FOR THEIR MANUFACTURE, THEIR USE AND MEDICINES CONTAINING THEM Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1987-08-19 EP claimed
WO-1987001114-A2 NEW AMINES, PROCESS FOR THEIR MANUFACTURE, THEIR USE AND MEDICINES CONTAINING THEM BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1987-02-26 WO claimed
US-6906078-B2 Method of using (H+/K+) ATPase inhibitors as antiviral agents PHARMACIA CORPORATION (US) 2005-06-14 US disclosed
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 US disclosed
US-5945425-A ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE G.D. SEARLE & CO. (US) 1999-08-31 US disclosed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 WO disclosed
US-5294439-A Stabilized benzimidazole derivative and composition NIPPON CHEMIPHAR CO., LTD. (JP) 1994-03-15 US disclosed
EP-0248634-B1 STABILIZED BENZIMIDAZOLE DERIVATIVE AND COMPOSITION NIPPON CHEMIPHAR CO., LTD. (JP) 1993-07-21 EP disclosed
EP-0218336-B1 USE OF BENZYLSULFINYLBENZIMIDAZOLES AS CYTOPROTECTIVE AGENTS FOR THE GASTROINTESTINAL TRACT NIPPON CHEMIPHAR CO., LTD. (JP) 1991-12-18 EP disclosed
US-4824856-A Method of protecting gastrointestinal tract NIPPON CHEMIPHAR CO., LTD. (JP) 1989-04-25 US disclosed
EP-0248634-A2 Stabilized benzimidazole derivative and composition NIPPON CHEMIPHAR CO., LTD. (JP) 1987-12-09 EP disclosed
EP-0232399-A1 NEW AMINES, PROCESS FOR THEIR MANUFACTURE, THEIR USE AND MEDICINES CONTAINING THEM Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1987-08-19 EP disclosed
EP-0218336-A2 Use of benzylsulfinylbenzimidazoles as cytoprotective agents for the gastrointestinal tract NIPPON CHEMIPHAR CO., LTD. (JP) 1987-04-15 EP disclosed
WO-1987001114-A2 NEW AMINES, PROCESS FOR THEIR MANUFACTURE, THEIR USE AND MEDICINES CONTAINING THEM BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1987-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents ATP4A, ATP1A1, ATP1A4 PRMT5 3499/4885WDR77 1186/4885ATP4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.